Big Phar­ma hits pause on tri­als in Rus­sia, Ukraine as they ramp up hu­man­i­tar­i­an aid

Phar­ma com­pa­nies across the board are ral­ly­ing to pro­vide hu­man­i­tar­i­an aid amid a bloody war in Ukraine that’s tak­en the lives of at least hun­dreds of civil­ians.

Yet as clin­i­cal tri­als re­main un­der threat of dis­rup­tion and a cor­po­rate ex­o­dus out of Rus­sia con­tin­ues, all the signs point to sig­nif­i­cant chal­lenges ahead for Big Phar­ma.

Ru­ud Dob­ber, head of As­traZeneca’s bio­phar­ma­ceu­ti­cals busi­ness unit, re­vealed ear­li­er this week at Cowen’s Health­care Con­fer­ence that the phar­ma gi­ant has sus­pend­ed en­roll­ment of some clin­i­cal tri­als in Ukraine and Rus­sia as the war en­ters its 13th day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.